Misinformation
7
1
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Protecting Against Lenacapavir Misinformation With Young Women in Gauteng, South Africa ( PROTECT-L)
Protecting Against HIV Vaccine Misinformation With Adolescent Girls and Young Women in South Africa
Brief Digital Intervention to Increase COVID-19 Vaccination Among Individuals With Anxiety or Depression
Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere
Leveraging Community Health Workers to Combat COVID-19 and Mental Health Misinformation in Haiti, Malawi, and Rwanda
Migrant Workers' Responses to the COVID-19 Pandemic
Contagious Misinformation Trial